Thromboxane Responsiveness of Dog Platelets Is Inherited as an Autosomal Recessive Trait

Gerhard J Johnson; Linda A Leis; Richard A King

doi:10.1055/s-0038-1648193

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1991; 65(05): 578-580
DOI: 10.1055/s-0038-1648193

Original Article

Schattauer GmbH Stuttgart

Thromboxane Responsiveness of Dog Platelets Is Inherited as an Autosomal Recessive Trait

Gerhard J Johnson

The Hematology/Oncology Section, Veterans Affairs Medical Center and Medical Genetics Division, Department of Medicine, University of Minnesota, Minneapolis, MN, U.S.A.

,

Linda A Leis

The Hematology/Oncology Section, Veterans Affairs Medical Center and Medical Genetics Division, Department of Medicine, University of Minnesota, Minneapolis, MN, U.S.A.

,

Richard A King

The Hematology/Oncology Section, Veterans Affairs Medical Center and Medical Genetics Division, Department of Medicine, University of Minnesota, Minneapolis, MN, U.S.A.

› Institutsangaben

Abstract

als PDF herunterladen

Summary

Most mongrel dogs have platelets that form thromboxane A₂ (TXA₂) from exogenous arachidonate, but they fail to aggregate or secrete in response to it. In contrast to these TXA₂ insensitive (TXA_2-) platelets, some dogs have TXA₂ sensitive (TXA₂₊) platelets that aggregate and secrete when stirred with arachidonate. To evaluate the possible genetic basis for this difference, we carried out seven matings of mongrel dogs that yielded 48 viable offspring. Four matings of dogs with TXA_2- platelets (presumed genotype TT) including 2 back-crosses, produced 32 pups with TXA_2- (TT) platelets and 0 pups with TXA₂₊ platelets. A cross between a male with TXA₂₊ platelets (presumed genotype tt) and a female with TXA₂₊ (tt) platelets yielded 9 offspring with TXA₂₊ (tt) platelets and 0 with TXA_2- platelets. Crossing a male presumed homozygous (TT) for TXA₂- platelets with a female with TXA₂₊ (tt) platelets produced 2 pups with TXA_2- (Tt) platelets and 0 pups with TXA₂₊ (tt) platelets. The same female with TXA₂₊ platelets crossed with a male presumed to be heterozygous (Tt) for TXA_2- platelets yielded 2 pups with TXA₂₊ (tt) platelets and 3 pups with TXA_2- (Tt) platelets. Segregation analysis of these data supports the hypothesis that the ability of dog platelets to aggregate and secrete in response to TXA₂ is inherited as an autosomal recessive trait.

PDF (610 kb)

Referenzen

References
1 Chignard M, Vargaftig B. Dog platelets fail to aggregate when they form aggregating substances upon stimulation with arachidonic acid. Eur J Pharmacol 1976; 38: 7-18
2 Chignard M, Vargaftig BB. Synthesis of thromboxane A₂ by nonaggregating dog platelets challenged with arachidonic acid or with prostaglandin H₂ . Prostaglandins 1977; 14: 222-240
3 Charo IF, Feinman RD, Detwiler TC, Smith JB, Ingerman CM, Silver MJ. Prostaglandin endoperoxides and thromboxane A₂ can induce platelet aggregation in the absence of secretion. Nature 1977; 269: 66-69
4 Johnson GJ, Leis LA, Rao GHR, White JG. Arachidonate-induced platelet aggregation in the dog. Thromb Res 1979; 14: 147-154
5 Johnson GJ, Rao GHR, Leis LA, White JG. Effect of agents that alter cyclic AMP on arachidonate-induced platelet aggregation in the dog. Blood 1980; 55: 722-729
6 Clemmons RM, Meyers KM. Acquisition and aggregation of canine blood platelets: Basic mechanisms of function and differences because of breed origin. Am J Vet Res 1984; 45: 137-144
7 Johnson GJ, Rao GHR, White JG. Platelet dysfunction induced by parenteral carbenicillin and ticarcillin: Studies of the dose-response relationship and mechanism of action in dogs. Am J Pathol 1978; 91: 85-106
8 Wu KK, LeBreton GC, Tai HH, Chen YC. Abnormal platelet response to thromboxane A₂ . J Clin Invest 1981; 67: 1801-1804
9 Lages B, Malmsten C, Weiss HJ, Samuelsson B. Impaired platelet response to thromboxane A₂ and defective calcium mobilization in a patient with a bleeding disorder. Blood 1981; 57: 545-552
10 Samama M, Lecrubier C, Conrad J, Hotchen M, Breton-Gorius J, Vargaftig B, Chignard M, Legarde M, Dechavanne M. Constitutional thrombocytopathy with subnormal response to thromboxane A₂ . Br J Haematol 1981; 48: 293-303
11 Hattori A, Takahashi H, Takahashi M, Shibata A, Okuma M. A new familial defect of platelet release mechanism (The intracellular Ca⁺⁺ transport defect?). Acta Haematol Jpn 1981; 44: 969-972
12 Okuma M, Takayama H, Uchino H. Subnormal platelet response to thromboxane A₂ in a patient with chronic myeloid leukaemia. Br J Haematol 1982; 51: 469-477
13 Ushikubi F, Okuma M, Kanaji K, Sugiyama T, Ogorochi T, Narumiya S, Uchino H. Hemorrhagic thrombocytopathy with platelet thromboxane A₂ receptor abnormality: defective signal transduction with normal binding activity. Thromb Haemostas 1987; 57: 158-164
14 Dunlop PC, Leis LA, Johnson GJ. A canine model of defective thromboxane A₂ receptor-G_p interaction. FASEB J 1990 4. A1915
15 Antiplatelet Trialist’s Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-331
16 Reilly IAG, FitzGerald GA. Aspirin in cardiovascular disease. Drugs 1988; 35: 154-176
17 Steering Committee of the Physician’s Health Study Research Group. Final report on the aspirin component of the ongoing physician’s health study. N Engl J Med 1989; 321: 129-135
18 Freeman MB, Sicard GA, Allen BT, Neuberger SM, Mathias CJ, Anderson CB. Endogenous canine thrombogenicity is equally important in vascular graft patency as platelet inhibition. Surg Forum 1986; 87: 453-456
19 Allen BT, Sicard GA, Mathias CJ, Welch MJ, Clark RE. Platelet deposition on vascular grafts. The accuracy of in vivo quantitation and the significance of in vivo platelet reactivity. Ann Surg 1986; 203: 318-328